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Undifferentiated stem cells, which drive embryogenesis and development, are often responsible for adult tissue maintenance and regeneration in response to injury \[[@CR1]\]. Stem cells are defined by their long-term ability to divide and self-renew and their ability to give rise to specialized cell types through differentiation. Stem cells are classified by the range of their potential to differentiate into specialized cells. For example, pluripotent stem cells are able to give rise to any embryonic cell type whereas multipotent stem cells can give rise to smaller subsets of more closely related cell types. Adult stem cells are specialized to specific tissues and are often multipotent. They are responsible for tissue homeostasis and regeneration after damage. While they are capable of self-renewal and differentiation, their "stemness" is reduced over time when grown in vitro \[[@CR1]--[@CR4]\]. Unlike adult stem cells, pluripotent and embryonic stem cells can give rise to all tissues found in the human body and are virtually unlimited in their ability to proliferate in vitro, making them attractive for use in biomedical research and regenerative medicine.

Human pluripotent stem cells (hPSCs) broadly refer to all pluripotent human stem cell types, including human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs). hESCs are most efficiently derived from the inner cell mass of human blastocytes generated during in vitro fertilization procedures \[[@CR5]\]. They are commonly grown in culture on either inactivated feeder layers of murine embryonic fibroblasts or under feeder-free conditions on tissue culture plates coated with a basement membrane protein substrate \[[@CR5]--[@CR7]\]. The development of conditions for feeder-free derivation and growth of hESCs \[[@CR6], [@CR8]--[@CR11]\] has enabled standardized production of cells more amenable for use in therapeutic applications (reviewed elsewhere \[[@CR12]\]).

One major challenge when using hESC-derived cells for therapeutic purposes is generating tissue for transplantation that will not be rejected by the patient's immune system. Another challenge for the use of hESCs has been the ethical opposition to destroying human embryos during hESC isolation and accordingly, strict rules exist regarding derivation and use of new hESC lines in projects reliant on US federal funding. Recently, methods to reprogram human or mouse "adult-like" somatic cells into "embryonic-like" stem cells was described by Shinya Yamanaka, a seminal discovery awarded the Nobel Prize in Medicine in 2012 \[[@CR13], [@CR14]\]. This method, called cellular reprogramming, was used to generate mouse and human iPSCs from fibroblast cells through the forced expression of a specific set of transcription factors (Oct4, Sox2, Klf4, c-Myc) \[[@CR15]--[@CR18]\]. These reprogrammed cells resemble hESCs in morphology and stem cell-defining characteristics, although detailed comparative gene expression studies suggest that there may be important differences between hESCs and iPSCs (reviewed elsewhere \[[@CR19]\]). The original protocol for iPSC generation involved use of retroviral vectors which leave a "genetic footprint" in the reprogrammed cell, raising concerns for the safety of using iPSCs for transplantation \[[@CR16]\]. In recent years, the methods have been further refined to eliminate the use of retroviruses \[[@CR18]\], thus making it possible to generate patient-specific iPSCs without changing the genetic composition of the cells.

hPSCs, embryonic and induced, can now be used to study and recapitulate many embryonic developmental stages in vitro. Translational embryology is an emerging field in which researchers are able to use what we know about different stages of embryonic development to direct differentiation of pluripotent stem cells into specialized cells and tissues (reviewed elsewhere \[[@CR20], [@CR21]\]). Directed differentiation is achieved by treating cells with recombinant proteins or small molecules that regulate important developmental signaling pathways, thereby mimicking key events during in vivo development. This approach has been used to generate a wide spectrum of cell types derived from all three primary germ layers (ectoderm, mesoderm, and endoderm), holding great promise for studies and treatments of many diseases \[[@CR21], [@CR22]\]. This review focuses on recent advances that used directed differentiation to generate intestinal tissue from hPSCs.

Growing the Intestine In Vivo {#Sec2}
=============================

Differentiation of hESCs or iPSCs into intestinal tissue requires a step-wise process mimicking major developmental events including definitive endoderm differentiation, gut specification and morphogenesis, and intestine development, growth, and homeostasis. We will briefly highlight these major developmental milestones. The three primary germ layers, generated in the process of gastrulation during embryogenesis, all contribute to the development of the intestine. The enteric nervous system that innervates the gut arises from the ectoderm; the smooth muscle, connective tissue, and vasculature of the gut arise from the mesoderm; and intestinal epithelium arises from the endoderm \[[@CR23]--[@CR26]\]. For the purpose of this review, we will focus on the development of the intestinal epithelium.

The TGF-β superfamily member Nodal is essential for the specification of endoderm. Variable levels of exposure to this growth factor control anterior--posterior (A--P) patterning of the endoderm \[[@CR27]\]. Fibroblast growth factor (FGF), Wnt, bone morphogenetic protein (BMP), and retinoic acid signaling are also involved in A--P patterning and induction of tissue-specific transcription factors (reviewed elsewhere \[[@CR23], [@CR28]\]). Simultaneous with formation of the gut tube, the endoderm is specified into future intestinal epithelium primarily through the induction of the transcription factor Cdx2 \[[@CR29]--[@CR32]\]. At this stage, the intestine is a single layer of Cdx2+ cuboidal epithelial cells that transitions to become a pseudostratified epithelium. The subsequent rapid expansion and thickening of the pseudostratified epithelium is responsible for increasing the length and girth of the intestine \[[@CR33], [@CR34]\]. Substantial remodeling then takes place, forming a single layer of columnar epithelium. The formation of the columnar epithelium is coincident with the emergence of villi and highly proliferative intervillus regions \[[@CR35]--[@CR37]\]. The mechanistic details of villus morphogenesis and formation of the intervillus regions is not entirely known; nevertheless, evidence suggests crosstalk between the epithelium and mesenchyme through the Hedgehog, BMP, platelet-derived growth factor (PDGF), transforming growth factor (TGF)-β, and Wnt pathways are important for the process (reviewed elsewhere \[[@CR24], [@CR38]\]). Transcription factors such as Gata4 and Gata6 are later involved in the specification of proximal versus distal intestine \[[@CR39]--[@CR41]\], although other less well understood factors are also likely involved.

After villus morphogenesis is complete, epithelial proliferation becomes restricted to the intervillus regions of the embryonic intestine. It is generally speculated that the cells in the intervillus region may give rise to the adult stem cells residing in the crypts of Lieberkühn, however, this has not been formally demonstrated. Notably, many of the best characterized adult intestinal stem cell (ISC) markers are not expressed in the proliferative embryonic intervillus domain \[[@CR42], [@CR43]\], suggesting that proliferating embryonic progenitor cells and adult stem cells in the crypt are not molecularly equivalent. Five differentiated cell types appear during and after emergence of villi: enterocytes (or colonocytes in the large intestine), goblet, tuft, enteroendocrine, and M-cells \[[@CR44], [@CR45]\]. In the mouse, Paneth cells appear in the small intestine only after crypts develop postnatally \[[@CR42]\].

Once the crypts emerge during intestinal maturation, Wnt/β-catenin and Notch signaling are two critical pathways involved in the regulation of intestinal proliferation and cytodifferentiation (reviewed elsewhere \[[@CR46]\]). Since many molecular markers of ISC are Wnt target genes, it is likely that Wnt signaling is essential for ISC maintenance \[[@CR47]\]. Wnt signaling also controls Paneth cell differentiation, consistent with the spatial co-localization of ISCs and Paneth cells at the base of the crypts where Wnt signals are high \[[@CR48]\]. The Notch pathway is critical for ISC self-renewal and differentiation \[[@CR49]--[@CR51]\] (reviewed in \[[@CR52]\]). During differentiation, Notch/Hes1 signaling in absorptive cells opposes expression of the secretory transcription factor Atoh1/Math1 \[[@CR50], [@CR53], [@CR54]\]. Further specification of secretory cell types occurs downstream of Atoh1/Math1 through Neurogenin3 \[[@CR55], [@CR56]\] for enteroendocrine cells, Gfi1, and SPDEF \[[@CR57]--[@CR59]\] for goblet cells, and Gfi1, Sox9, and SPDEF for Paneth cells \[[@CR58]--[@CR62]\]. Crosstalk between the Wnt/β-catenin and Notch signaling pathways needs to be further elucidated given reports of Wnt also playing a role in cell fate decisions \[[@CR63]--[@CR66]\].

Growing Intestinal Tissue In Vitro {#Sec3}
==================================

Primary Intestinal Epithelial Culture Methods and Nomenclature {#Sec4}
--------------------------------------------------------------

Major breakthroughs in our understanding of ISC regulation have been made over the last few years \[[@CR36], [@CR49], [@CR67]--[@CR71]\]. These advances have, in turn, had several positive consequences including the identification of novel ISC markers, an explosion in the development of new genetic tools to identify and study ISCs in mice \[[@CR72]--[@CR76]\], opening new avenues to develop therapeutic drugs to treat intestinal cancer \[[@CR77]\], and technological breakthroughs enabling researchers to grow robust primary epithelial cultures from mouse and human intestine \[[@CR78]--[@CR80]\]. To date, many groups have published methodologies for growing primary intestinal epithelial cultures \[[@CR78]--[@CR83]\], which all include the core tenets that three-dimensional (3D) structure and high levels of Wnt signaling are critical to maintain long-term growth in vitro. Due to their robustness, development of these 3D culture methods have yielded powerful, physiologically relevant systems that facilitate the study of intestinal homeostasis \[[@CR48], [@CR51]\], gene regulation and function \[[@CR48], [@CR84], [@CR85]\], and have additional promise for the performance of biochemical assays and drug screens. High Wnt signaling and 3D intestinal culture conditions \[[@CR78], [@CR79]\] enabled the expansion of human embryonic gut-like tissue derived from hPSCs into more mature human intestinal "organoids" \[[@CR31], [@CR86]\] (see "[Generating Induced Human Intestinal Organoids (iHIOs)](#Sec5){ref-type="sec"}" section).

Given the diverse methods and tissue sources for primary intestinal cultures, there has been a recent initiative for the gastrointestinal research community to adopt a common nomenclature \[[@CR87]\] (Table [1](#Tab1){ref-type="table"}), although to date, a consensus has not been reached. This may be due, in part, to the fact that one of the original papers describing intestinal epithelial culture conditions referred to the resulting 3D structures as "intestinal organoids" \[[@CR78]\]. These "organoids," described by Sato et al. \[[@CR78]\] are epithelial in nature, and contain no mesenchyme. Further, these epithelial-only cultures have been published and referred to as organoids in more than 30 publications since 2009. Stelzner et al. \[[@CR87]\] proposed that these epithelial cultures be re-coined "enteroids," since they are solely derived from the enteric epithelium and that the term "organoid" be reserved for tissue that more closely resembles the organ proper, composed of multiple tissue types including the epithelial and mesenchymal components characteristic of native intestine. Stelzner et al. also suggest referring to in vitro generation of intestinal tissue from non-intestinal sources as "induced" intestine. For the purposes of this review, we will refer to intestine derived from human embryonic or iPSCs as "induced human intestinal organoids" (iHIOs). As the suggested system for nomenclature implies, iHIOs contain epithelial and mesenchymal tissue. We caution readers not to confuse iHIOs with epithelial-only cultures derived from isolated intestinal epithelium, crypts or single ISCs (Table [1](#Tab1){ref-type="table"}).Table 1Description of terms and abbreviationsAbbreviationsFull nameDescriptionhESCHuman embryonic stem cellPluripotent cells derived from human embryoiPSCInduced pluripotent stem cellsPluripotent cells derived from reprogrammed somatic cellsSpheroidIntestinal spheroid or mid/hindgut spheroid3D structure generated from human endoderm, resembling early embryonic gut tissue. Spheroids expand and give rise to iHIOsOrganoidOrganoid3D organ-like structure grown in vitro that resembles a complex organ in vivo, including multiple cell and tissue typesiHIOInduced human intestinal organoid3D intestinal tissue generated from pluripotent stem cells, comprised of intestinal epithelial and mesenchymal tissueEnteroidEnteroidPrimary intestinal epithelium grown in culture, can be generated from mouse or human intestinal epithelium

Generating Induced Human Intestinal Organoids (iHIOs) {#Sec5}
-----------------------------------------------------

As already highlighted, human embryonic and iPSCs have been highly touted for their potential to treat or cure disease through cell-based transplantation therapies. Nevertheless, the potential for hPSCs goes far beyond that of transplantation. hPSCs also hold amazing potential to accurately mimic human development, homeostasis, and disease in vitro. Work over the past decade has focused on understanding regulation of pluripotency and differentiation in hPSCs. More recently, directed differentiation has emerged as the most efficient approach to achieving in vitro generation of a cell or tissue of interest \[[@CR48], [@CR82], [@CR83], [@CR88]--[@CR102]\]. Many breakthroughs in pluripotent stem cell differentiation have occurred using two-dimensional (2D) culture conditions directed at generating a single cell type of interest. In contrast, generation of 3D organ units (organoids) or more complex tissue from hPSCs has only recently been recognized as a viable approach for differentiation \[[@CR31], [@CR103], [@CR104]\]. Such 3D models will offer complex multi-lineage, multi-cellular systems that can more closely recapitulate both normal physiology as well as pathological conditions in vitro, forming the basis for new in vitro human models designed to help understand normal homeostasis, complex multigenic diseases, perform drug screens, and validate the efficacy of new drugs prior to clinical trials \[[@CR105]\].

Using directed differentiation, we were able to successfully generate 3D intestinal tissue by recapitulating embryonic development of the intestine in vitro \[[@CR31], [@CR86]\]. We employed a step-wise differentiation protocol that included endoderm induction, A--P patterning, intestinal lineage commitment, and intestinal growth and differentiation (Fig. [1](#Fig1){ref-type="fig"}). In the embryo, as cells migrate through the primitive streak, they are exposed to Nodal, a TGFß family member. Depending on the concentration and time of exposure to Nodal signaling, cells adopt either a mesodermal or endodermal fate *en route* to forming their proper germ layer \[[@CR106]--[@CR117]\]. In hPSCs, robust and efficient endoderm induction is achieved by mimicking Nodal signaling using Activin A \[[@CR20], [@CR88], [@CR118]\]. We are routinely able to generate human endoderm cultures with \>85 % efficiency, determined by co-staining of the transcription factors SOX17 and FOXA2 using a well-established 3-day differentiation protocol \[[@CR31], [@CR88]\]. Following induction, we consider the resulting human FOXA2+/SOX17+ endodermal tissue to be naive, capable of giving rise to all endodermal lineages including pancreatic (PDX1+), hepatic (ALB+), biliary (SOX17+), and intestinal (CDX2+) \[[@CR31], [@CR119]\].Fig. 1Schematic of human pluripotent stem cell-derived intestinal organoids. Human-induced pluripotent (iPSC) or embryonic (hESC) stem cells are differentiated into FOXA2/SOX17 positive endoderm with \>85 % efficiency. A small proportion of cells (\~2--5 %) also differentiate into Brachyury (T)-positive mesoderm. Induction of the intestinal epithelial transcription factor CDX2 is achieved by activating FGF and WNT signaling for 4 days. The mesenchymal population expands and expresses the intestine--mesenchyme transcription factor FOXF1. During this 4-day induction, 3D spheroids comprised of CDX2+ epithelial and FOXF1+ mesenchymal layers form, and delaminate from the tissue culture dish. Spheroids are then cultured in a 3D matrix (Matrigel) in "high WNT" conditions (WNT3A and/or RSPO1) along with EGF and Noggin (NOG). During the first month in culture, spheroids expand drastically in size, giving rise to iHIOs. iHIOs can be split and re-cultured, and maintained for many months in vitro

During endoderm induction, the embryo simultaneously undergoes complex morphogenetic movements and patterning events to give rise to the early gut tube, which is patterned into different domains along the A--P and dorsal--ventral (D--V) axes with the different domains giving rise to different subsets of endodermal organs \[[@CR23], [@CR109], [@CR120]--[@CR124]\]. Of note, work done in a host of vertebrate organisms has shown that an increasing anterior-to-posterior gradient of FGF, WNT and BMP signaling acts to posteriorize the endoderm \[[@CR28], [@CR125]--[@CR129]\]; WNT and/or FGF signaling is able to induce human endoderm towards CDX2+ intestinal lineages \[[@CR31], [@CR32]\]. In FGF4 + WNT3A treated induced human endoderm, we observed robust and stable induction of CDX2 in \~95 % of cells after 96 h of treatment. Remarkably, we also observed dramatic morphogenetic movements in the tissue culture dish, which gave rise to gut-like "spheroids," which were small 3D clusters of cells that budded from the underlying monolayer. These spheroids were comprised of an inner epithelial layer and outer mesenchymal layer. Although the mechanisms downstream of FGF and/or WNT signaling that govern these complex in vitro morphogenetic tissue movements are unclear, this system will likely be an excellent tool to study how complex tissue movements and tube formation occurs.

Following spheroid formation, we took advantage of pro-intestinal conditions established by Sato et al. \[[@CR78]\] and continued to culture spheroids embedded in Matrigel and medium supplemented with recombinant human growth factors that promoted high levels of WNT signaling (WNT3A and/or RSPO1). Spheroid size and complexity increased remarkably over 1 month, giving rise to an epithelial and mesenchymal layer. The epithelium expressed molecular markers typical of many small intestinal cell types, including enteroendocrine cells (chromogranin A), goblet cells (mucin2), Paneth cells (lysozyme), and enterocytes (dipeptidyl peptidase (DPP)4, villin). We also observed that when iHIOs were cultured for \>2 months, expression of ISC markers such as achaete-scute complex homolog 2 (ASCL2) and leucine-rich repeat-containing G-protein coupled receptor 5 (LGR5) were observed. Using iHIOs, we have published a limited number of experiments to show that the epithelium appears to be functional and behaves in a normal physiological manner. For example, the epithelium in iHIOs is turned over every 6--7 days, similar to intestinal cell turnover in vivo \[[@CR84], [@CR130]--[@CR132]\]. We have also demonstrated that iHIOs have a functional enterocyte peptide transport system by visualizing transport of a fluorescently labeled dipeptide \[[@CR31], [@CR133]\].

Experimental Utility of iHIOs and Enteroids {#Sec6}
===========================================

Epithelial-only enteroids generated from adult mouse or human intestinal epithelium have a proven track record as a highly useful tool for studying physiologically relevant events, such as ISC regulation and differentiation. In this light, it is important to highlight some of the advantages that iHIOs have to offer, as well as to point out potential disadvantages compared to enteroid cultures. One of the most significant advantages iHIOs offer is the ability to use this model to study human embryonic events in vitro. We have demonstrated that, much like the developing intestine in vivo, iHIOs transition from an early hindgut-like stage into a pseudostratified epithelium, which then undergoes tissue rearrangements that give rise to a columnar epithelium that has villus-like structures and proliferating intervillus-like domains \[[@CR31], [@CR38]\]. Further, development and differentiation of specialized cell types in the normal intestine are reflected in iHIOs. For example, we demonstrated that knockdown or overexpression of Neurog3 led to a respective decrease or increase of enteroendocrine cells in iHIOs, consistent with the described role of Neurog3 in humans and mice \[[@CR31], [@CR55], [@CR134]--[@CR136]\]. Recently, it has also been demonstrated that the transcription factor Arx is also critical for proper enteroendocrine development in the developing mouse intestine and in iHIOs \[[@CR137]\].

A second advantage of iHIOs is their multi-lineage composition. That is, iHIOs have an endodermally derived epithelial layer, and a mesodermally derived mesenchymal layer. The presence of both germ layers is a byproduct of the ActivinA endoderm differentiation protocol used in the first step in iHIO generation. While differentiation is very efficient, and routinely generates \~90 % endoderm, a small population of cells differentiate into Brachyury (T)-positive mesodermal progenitors that give rise to FoxF1+ intestinal mesenchymal progenitors. The iHIO mesenchymal layer, while disorganized, is comprised of multiple cell types, including smooth muscle (smooth muscle actin +), intestinal subepithelial myofibroblasts (ISEMF), and fibroblasts \[[@CR31]\]. Since iHIOs possess this mesenchymal layer, they can be used to study intestinal mesenchymal biology in addition to epithelial-mesenchymal interactions.

A third advantage of iHIOs is the ability to generate patient-specific intestinal tissue for the study of human disease. With the recent advances in generating induced pluripotent stem cell lines \[[@CR15], [@CR16]\], it is now possible to generate intestinal tissue from patients with specific diseases. Although likely possible, it is currently unclear whether enteroids (epithelium only) can be generated from diseased or damaged epithelium.

Coupling these two in vitro systems (iHIOs and enteroids) to study intestinal disease will be ideal given their distinct advantages. For example, iHIOs will enable the study of "healthy" intestinal tissue from an individual whereas enteroids from the same individual will have been exposed to the disease environment in vivo. For example, iHIOs generated from individuals with inflammatory bowel disease (IBD) will have "healthy," non-inflamed intestinal tissue, with no exposure to the immune system whereas enteroids from the same patient will have had exposure to inflammation and the immune system. Therefore, intestinal tissue that has been in a disease-state (enteroids) and a non-disease state (iHIOs) from this patient can be examined, compared and experimentally manipulated. In this light, iHIOs will be a very powerful tool to elucidate the pathogenesis of complex multigenic human diseases.

Perspectives {#Sec7}
============

Emerging evidence suggests that iHIOs will be useful for a wide variety of studies, such as infectious diseases \[[@CR138]\]. As iHIOs are more widely adopted as a model to study human intestinal biology and pathobiology, their true utility and limitations will become more apparent. The significance of having complex, multi-lineage (mesenchyme, epithelium) 3D human intestinal tissue as a model experimental system will likely be unparalleled. In this light, it will be exciting to see how the scientific community puts this novel system to use.
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